161 related articles for article (PubMed ID: 10850521)
1. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.
Gajjar DA; LaCreta FP; Uderman HD; Kollia GD; Duncan G; Birkhofer MJ; Grasela DM
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):49S-58S. PubMed ID: 10850521
[TBL] [Abstract][Full Text] [Related]
2. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise.
Gajjar DA; LaCreta FP; Kollia GD; Stolz RR; Berger S; Smith WB; Swingle M; Grasela DM
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):76S-86S. PubMed ID: 10850524
[TBL] [Abstract][Full Text] [Related]
3. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults.
LaCreta FP; Kaul S; Kollia GD; Duncan G; Randall DM; Grasela DM
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):59S-66S. PubMed ID: 10850522
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients.
Kanji S; McKinnon PS; Barletta JF; Kruse JA; Devlin JW
Crit Care Med; 2003 May; 31(5):1347-52. PubMed ID: 12771601
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
Stass H; Kubitza D; Schühly U
Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
[TBL] [Abstract][Full Text] [Related]
8. Age and gender effects on the pharmacokinetics of gatifloxacin.
LaCreta FP; Kollia GD; Duncan G; Behr D; Grasela DM
Pharmacotherapy; 2000 Jun; 20(6 Pt 2):67S-75S. PubMed ID: 10850523
[TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
Geisser P; Banké-Bochita J
Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit.
Fish DN
Int J Antimicrob Agents; 2007 Jun; 29(6):715-23. PubMed ID: 17433631
[TBL] [Abstract][Full Text] [Related]
13. Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval).
Morganroth J; Talbot GH; Dorr MB; Johnson RD; Geary W; Magner D
Clin Ther; 1999 May; 21(5):818-28. PubMed ID: 10397377
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of sparfloxacin in patients with renal impairment.
Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH
Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerance, and preliminary pharmacokinetics of nefazodone after administration of single and multiple oral doses to healthy adult male volunteers: a double-blind, phase I study.
Barbhaiya RH; Marathe PH; Greene DS; Mayol RF; Shukla UA; Gammans RR; Pittman KA; Robinson D
J Clin Pharmacol; 1995 Oct; 35(10):974-84. PubMed ID: 8568015
[TBL] [Abstract][Full Text] [Related]
17. Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.
Allen A; Bygate E; Vousden M; Oliver S; Johnson M; Ward C; Cheon A; Choo YS; Kim I
Antimicrob Agents Chemother; 2001 Feb; 45(2):540-5. PubMed ID: 11158752
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
Rosenberg G; Angel I; Kozak A
Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
